Dendreon Sells Manufacturing Unit - Analyst Blog

By
A A A
Share |

Dendreon Corporation ( DNDN ) recently sold its immunotherapy manufacturing facility (IMF) to Novartis Pharmaceuticals Corporation ( NVS ) for $43 million in cash. The manufacturing facility was based in Morris Plains, New Jersey.

Dendreon's Morris Plains facility has the capability to manufacture Provenge, the first cellular immunotherapy approved in the US for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

In July this year, Dendreon announced a restructuring plan for 12 months. It was during that time the company decided to close down its Morris Plains unit. The company decided to operate through its Union City, GA and Seal Beach, CA facilities, which have a manufacturing capacity of approximately $1 billion of Provenge and can be doubled with the implementation of automation.

The company planned to reduce the number of employees by 600 (both full-time and contractual). The restructuring initiatives are expected to yield savings of approximately $150 million per year. The company expects to see the results of these initiatives from the first half of 2013 although the full benefit is expected in the third quarter of 2013.

Our Take

We believe Dendreon's strategic restructuring plan may help the company to swing to profitability. Dendreon's growth is dependent on its prostate cancer drug Provenge. Hence, the successful commercialization of Provenge is crucial for the financial performance of Dendreon.

However, Provenge sales have failed to live up to management as well as investor expectations. We remain concerned about Dendreon's high dependence on Provenge for long-term growth.

We currently have a Neutral recommendation on Dendreon. The stock carries a Zacks #3 Rank (Hold). Other stocks in the pharma sector that carry a Zacks #1 (Strong Buy) Rank are Targacept ( TRGT ) and Repligen ( RGEN ).



DENDREON CORP (DNDN): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

REPLIGEN (RGEN): Free Stock Analysis Report

TARGACEPT INC (TRGT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: DNDN , IMF , NVS , RGEN , TRGT

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

89,970,926
  • $16.15 ▲ 0.12%
77,131,582
  • $58.94 ▼ 1.31%
67,336,935
  • $26.56 ▲ 1.68%
48,814,124
  • $86.20 ▲ 0.02%
47,526,126
  • $23.21 ▲ 0.78%
44,660,424
  • $23.91 ▲ 6.36%
38,799,699
  • $4.289 ▲ 4.36%
36,199,890
  • $40.01 ▼ 0.97%
As of 4/17/2014, 04:07 PM